about
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialPharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinInitial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trialPreliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMIA comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study GroupRandomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.Angiographical and Doppler flow-derived parameters for assessment of coronary lesion severity and its relation to the result of exercise electrocardiography. DEBATE study group. Doppler Endpoints Balloon Angioplasty Trial Europe.The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocaInfluence of naloxone on the effects of high frequency transcutaneous electrical nerve stimulation in angina pectoris induced by atrial pacingComparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.Sotalol-induced delayed ventricular repolarization in man.Effects of spinal cord stimulation in angina pectoris induced by pacing and possible mechanisms of actionPredictors of hospital readmission two years after coronary artery bypass grafting.The prognosis of patients suspected of having acute myocardial infarction subsequent to its exclusion as the diagnosis.Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.Eligibility for intravenous thrombolysis in suspected acute myocardial infarction.Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: the ESBY study.Effect of endoscopic transthoracic sympathicotomy on heart rate variability in severe angina pectoris.Spinal cord stimulation in angina pectoris with normal coronary arteriograms.Mechanisms of angina relief after nifedipine: a hemodynamic and myocardial metabolic study.Catecholamine metabolism during pacing-induced angina pectoris and the effect of transcutaneous electrical nerve stimulation.Clinical and Angiographic Results with the Multi-Linkª Coronary Stent System Ñ The West European Stent Trial (WEST).Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.Effects of thoracic epidural anesthesia on coronary arteries and arterioles in patients with coronary artery disease.Evaluation of the antianginal effect of nifedipine: influence of formulation dependent pharmacokinetics.[Emergency heart surgery in Gothenburg 1980-1984: early surgical treatment is more common in patients with severe acute heart diseases]Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) triaEffect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEInhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSEGöteborg Metoprolol Trial: enzyme-estimated infarct size.Clinical and Angiographic Results with the Multi-Linkª Coronary Stent System Ñ The West European Stent Trial (WEST).Determinants of time to discharge following coronary artery by pass grafting.Mortality and morbidity during a period of 2 years after coronary artery bypass surgery in patients with and without a history of hypertension.Can the results be explained by poor randomization and nonpertinent comparisons?Anti-ischemic and anti-anginal effects of thoracic epidural anesthesia versus those of conventional medical therapy in the treatment of severe refractory unstable angina pectoris.Thoracic epidural anesthesia improves global and regional left ventricular function during stress-induced myocardial ischemia in patients with coronary artery disease.
P50
Q28165358-25D216DB-4F90-47C9-83E1-F5B81FCA7C38Q28195019-045D93E7-F563-4FE7-9E8C-2526E5535E75Q28195423-9B51181B-D4E3-47B9-984F-8B88222CAA4BQ28222150-FAED5B78-5F46-4345-B340-A3DABD349883Q28245560-33BE6513-9F15-4C16-93EA-75FE59BD2070Q28281495-98511F7B-3F31-4705-A5C3-B3A0CDA65BDEQ30821177-751391F7-6762-4DD4-AAF9-C83C0171D1AAQ30840315-D86EA53D-9C72-4C4D-A5F3-C6F91B86ECCEQ33160009-FBE32BE4-D173-4B21-892D-FCE6D7CD8F62Q34000226-15E6161B-0976-4E86-8FF6-53BBEA6DA95BQ34093139-1EEFC665-341E-4CC0-A47E-853A26838B82Q34717403-D6F2A5BB-D819-47B3-9C4E-037553370FAEQ35189525-D302871E-F356-4E51-BFDD-715EE2BD9340Q36843399-381F217A-5705-4D8A-B601-288C6F713509Q37906025-74C179A8-7E89-4C90-AEE2-769824D7E2A5Q38497913-CFEEEADE-26D3-4016-909E-68014CBB769AQ39271112-87A190D4-7E28-4A5A-906B-9010B1339356Q39449463-E4591F19-DA62-41D7-BBD3-794CC06D8A34Q39455500-0C578D2F-51DF-4CDE-9951-CBDB5EFB3C9CQ39491255-0A934919-786D-4499-8D78-C4614BBC341AQ39558924-B2ACD09D-F197-4440-98A6-E394A52AA6A3Q41448521-F35A73DA-BCDF-48E5-A6F9-DBDFC8CA92F0Q42623951-B2061964-A340-464E-AF62-2440CED4AF89Q42910350-5A08ADFB-2448-4636-9BD5-55C2479865FAQ43662280-19C79A06-A029-4098-A1D7-9086D7C4622EQ44305155-AF4CA9B9-503F-4827-A438-8AAB116BF683Q44770266-4042F3B3-6380-4081-AF5E-5C6A475384ADQ45710707-2FBE928B-7A44-4137-A4AF-FEAC62DB7CBDQ46067067-B86D57A3-E873-4C21-BBD4-8E5A5C1DEE48Q46068914-28FA5B77-67B5-4A89-B672-C1F270A451CFQ46794300-60411A16-96CE-466D-84B4-22DB3DD081D1Q46916589-4221D113-CE1B-41EA-A472-B0E7D6D87BDEQ46916592-5787A93D-74A1-4B34-912D-9A95609DF428Q47238089-6F92E355-50F9-49DB-BD6E-BF73D069020DQ50133452-A7D97CFF-E699-4650-A702-94E8B7F623AAQ50961735-112349CE-261B-420C-885A-2E3FFE86B41AQ51020959-08536B00-C9A6-459B-B26F-422541674967Q51407791-C9862A21-B5AC-4AF6-97E4-B2500E46B101Q51535555-595BCBB3-3F82-4C68-9E0E-C84EB0740CDCQ51723203-185066F0-06D5-42D1-A914-4FD8F339F158
P50
description
Swedish researcher
@en
Zweeds onderzoeker
@nl
svensk forsker
@nb
name
Håkan Emanuelsson
@da
Håkan Emanuelsson
@de
Håkan Emanuelsson
@en
Håkan Emanuelsson
@es
Håkan Emanuelsson
@fr
Håkan Emanuelsson
@nb
Håkan Emanuelsson
@nl
Håkan Emanuelsson
@nn
Håkan Emanuelsson
@sl
Håkan Emanuelsson
@sv
type
label
Håkan Emanuelsson
@da
Håkan Emanuelsson
@de
Håkan Emanuelsson
@en
Håkan Emanuelsson
@es
Håkan Emanuelsson
@fr
Håkan Emanuelsson
@nb
Håkan Emanuelsson
@nl
Håkan Emanuelsson
@nn
Håkan Emanuelsson
@sl
Håkan Emanuelsson
@sv
prefLabel
Håkan Emanuelsson
@da
Håkan Emanuelsson
@de
Håkan Emanuelsson
@en
Håkan Emanuelsson
@es
Håkan Emanuelsson
@fr
Håkan Emanuelsson
@nb
Håkan Emanuelsson
@nl
Håkan Emanuelsson
@nn
Håkan Emanuelsson
@sl
Håkan Emanuelsson
@sv
P106
P2038
Hakan_Emanuelsson